A Clinical Study to Evaluate the Pharmacokinetic Profile of SB-649868 in Elderly and Female Population

GlaxoSmithKline (GSK)

Status and phase: Withdrawn; Phase 1

Conditions: Insomnia

Treatments: Drug: SB-649868

Study type: Interventional

Funder types: Industry

Identifiers

NCT00534872

OXS109143

Details and patient eligibility

About

The purpose of this study is to determine the blood levels and the tolerability of SB-649868 in Elderly and Female population

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy adult and elderly female and male
• Female must be of non-childbearing potential
• Body weight =50 kg

Exclusion criteria

• Abuse of alcohol or drugs
• Positive for Hepatitis B surface antigen, Hepatitis C antibody or HIV
• Use of prescription or non-prescription drugs within 7 days prior to the first dose of study medication
• Smoking history of = 10 cigarettes a day in the last three months
• History of cardiovascular,psychiatric,autoimmune, respiratory or relevant gastrointestinal diseases
• Participation in clinical trial during the previous 6 months

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

0 participants in 1 patient group

SB649868

Experimental group

Description:

10 mg

Treatment:

Drug: SB-649868